SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk ($NVO) is trending due to a mix of reactions to a failed Alzheimer's drug trial and anticipation surrounding the upcoming launch of its weight loss pill; the Alzheimer's news triggered a sharp sell-off, with the community debating whether the market overreacted, considering obesity treatments are the company's core business.  Bullish investors view the dip as a buying opportunity ahead of the potential approval of the weight loss pill, while others are concerned about increased competition from companies like Eli Lilly ($LLY) and potential price cuts in the GLP-1 market.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

OSCR is trending due to uncertainty around the extension of ACA subsidies and potential impacts on the company's future profitability, with community members discussing various scenarios and price levels. The stock experiences volatility as investors weigh the potential implications of policy changes and management's strategic direction, while some highlight the company's cash position and long-term growth prospects. Discussions also involve potential influence from political figures and strategic positioning amidst evolving healthcare policies.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending as reports surface alleging the company provides technological support to the Chinese military, raising concerns about national security and data access; however, the company denies these allegations. The community is weighing the potential impact of this news amid mixed sentiment leading up to earnings, while some see this as an opportunity to buy the dip, others anticipate further downward pressure.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending amid discussions around its potential involvement in the Jeffrey Epstein case and differing opinions on Jamie Dimon's stance on crypto. The community is divided, with some calling for boycotts and others defending the bank's position; also, there is discussion surrounding JPM's recent moves in the crypto space, with some interpreting these moves as hypocritical.

Pony.ai, Inc. develops artificial intelligence-based robot designed for autonomous driving. The firm's software algorithms and infrastructure enables a vehicle to perceive its surroundings, predict what others will do, and maneuver itself accordingly. The company was founded by Jun Peng and Tian Cheng Lou in November 4, 2016 and is headquartered in Guangzhou, China.

Pony AI Inc. - ADR

Pony AI Inc

Pony AI Inc is trending due to recent partnership expansions and anticipation for upcoming earnings. The community is discussing the significance of Pony AI's partnerships in scaling its robotaxi fleet and its potential market position against competitors. Investors are weighing the company's growth prospects against its financial performance, analyzing revenue streams and expansion strategies.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is trending due to significant revenue growth in its robotaxi business and global expansion efforts, including landmark regulatory approvals in the UAE and Switzerland. Community discussions highlight the company's impressive year-over-year growth in robotaxi revenue and expansion into new markets, although some concerns remain around the company's ability to scale and achieve profitability. Investors are closely watching WeRide's progress in deploying autonomous vehicle technology and securing partnerships with major players like Uber and Grab.

Monad

Monad is trending as users anticipate its official listing, with many sharing that they've received their tokens from the presale. The community is actively discussing allocation sizes and strategies, while also speculating on potential price movements. Some users are pointing out the high demand and comparing it to a traditional IPO.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is trending as the community discusses potential catalysts including the upcoming Q3 earnings report, a possible rebound in price, and speculation around a BONK ETF. Some traders are pointing to the strong Solana ecosystem and growing community support as reasons for optimism, while others highlight the upcoming 1 Trillion token burn. Community members are debating potential price movements and optimal entry points.

Meet Pandu — your AI friend who’s always by your side. Talk with him in real time through text or voice, share your thoughts, ask questions, or just enjoy a casual conversation. Whether you’re looking for advice, company, or simply someone to listen, Pandu is here as a true companion you can connect with anytime.  Pandu unites real-time conversation, creative generation, and future-ready AI systems — all powered by next-gen technology.

Pandu Pandas

Pandu Pandas ($PANDU) is trending as a Solana microcap with a growing community, with many highlighting its potential utility and strong community. The community is excited about upcoming announcements and believes $PANDU is more than just a memecoin, with some drawing comparisons to other successful projects on the Solana ecosystem. Recent listings and NFT offerings are also being discussed.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Recent buzz around GOOG centers on the launch of its Gemini 3 model, which is reportedly outperforming competitors in AI benchmark tests, fueling speculation about Google's dominance in the AI race. The community is actively discussing the implications for Google's growth, with some questioning its valuation amid broader concerns of an overbought market and others highlighting its potential to disrupt the AI landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge PR Newswire VANCOUVER, BC, Oct. 15, 2025 Equity Insider News...

CytoMed Therapeutics (GDTC) announced on Tuesday that it has submitted a cash bid for an undisclosed sum to the joint administrators of TC BioPharm, effective October 2, for the potential acquisition of its assets.The proposed acquisition will strengthen and deepen CytoMed’s expertise and knowledge in using allogeneic cell therapies for cancer treatment, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/14/3166116/0/en/CytoMed-makes-cash-bid-for-potential-acquisition-of-TC-BioPharm-Limited-s-relevant-assets.html">said</a>. The company added that this will help it accelerate its commercialization timeline.TC BioPharm and CytoMed are both clinical-stage biopharmaceutical companies engaged in the research and development of donor-derived allogeneic gamma delta T cells for cancer treatment. While TC BioPharm has completed an early-stage clinical trial, CytoMed is currently conducting an early-stage trial in Singapore, evaluating its chimeric antigen receptor (CAR) T cells for a broad range of liquid and solid cancers.The proposed acquisition will be funded by internal resources, the Singapore-based CytoMed said. Shares of the company traded 19% higher at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GDTC">GDTC stock</a> rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:623/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_14_at_11_07_48_AM_png_d20bc36299.webp" alt="GDTC's Sentiment Meter and Message Volume as of 11:08 a.m. ET on Oct. 14, 2025 | Source: Stocktwits" width="623" height="63"><figcaption>GDTC's Sentiment Meter and Message Volume as of 11:08 a.m. ET on Oct. 14, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes the stock might be gearing up for a breakout soon.<stembedurl>https://stocktwits.com/Nova_Trades/message/632225590</stembedurl>CytoMed acquired certain assets of Cellsafe International Sdn Bhd, a Malaysian cord blood bank, in October 2024. The acquisition included a cord blood banking license issued by Malaysia’s Ministry of Health, cryopreservation equipment with more than 12,000 cord blood units, and two freehold real estate properties in which the operation is situated.TC BioPharm is a unit of TC BioPharm Holdings Plc, which was listed on the Nasdaq until March earlier this year. The company said earlier this month that its directors have appointed Michael Magnay and Rob Croxen of Alvarez and Marsal Europe LLP as joint administrators to its unit to explore options for the sale of the business and assets. The company also said that the parent company continues to operate as usual.GDTC stock is down by 33% this year and up by about 6% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/candel-therapeutics-enters-130-million-dollar-loan-facility-to-advance-lead-product-candidate-in-treatment-of-lung-cancer/ch6mpu5R3mm">Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did CytoMed Therapeutics Stock Jump 19% Today?

The company said that the proposed acquisition of TC BioPharm will strengthen and deepen its expertise and knowledge in using allogeneic cell therapies for cancer treatment. 

Equity

The company said that the proposed acquisition of TC BioPharm will strengthen and deepen its expertise and knowledge in using allogeneic cell therapies for cancer treatment. 


CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration

SINGAPORE / ACCESSWIRE / March 20, 2024 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ('CytoMed' or 'the Company'), a Singapore biopharmaceutical company that focuses on utilizing its licensed...

CytoMed Launches Shareholder Cell Banking Program

CytoMed Therapeutics Limited (GDTC) has released an update. CytoMed Therapeutics Limited announces a pilot program offering free cell banking to it...

Cytomed Therapeutics to launch complimentary cell banking

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies

SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ( CytoMed or Company ), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair

CytoMed diversifies into regenerative medicineSINGAPORE, March 04, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ( CytoMed or Company ), a Singapore-based biopharmaceutical...

Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

The Company now has exclusive rights to a Malaysia, US and China patentSINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ( CytoMed or Company ), a...

CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. It operates through the Malaysia and Singapore geographical segments. The company was founded by Chee Kong Choo on March 9, 2018 and is headquartered in Singapore.

GDTC
CYTOMED THERAPEUTICS LIMITED

Feed

News

Sentiment

Fundamentals

Info

Latest GDTC News

GDTCCYTOMED THERAPEUTICS LIMITED